Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05987098
Other study ID # PekingUMCH-BBPA PET/CT
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date March 22, 2021
Est. completion date September 1, 2024

Study information

Verified date March 2024
Source Peking Union Medical College Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is an open-labeled phase II diagnostic clinical trial to explore the safety and clinical value of BBPA-PET/CT in suspected malignant tumor patients. The investigation regarding the clinical value of BBPA concerning the metabolic characteristics of BBPA in suspected malignant tumors. Quantitative features will be extracted to analysis the PET images. For patient who took surgery after multiple examination, histopathology, molecular pathology and LAT-1 immunohistochemistry will also be obtained.


Description:

In this study, we utilized BBPA, a novel boron amino acid, which replaces the carboxyl group of 4-boronate phenylalanine (BPA) with a boron trifluoride group (-BF3) (-COOH), as a diagnostic molecule for PET imaging of brain tumors, is also a highly efficient boron carrier for BNCT. Preclinical studies suggested [18F]BBPA to be a pan-cancer probe that transmembrane transported through large neutral amino acid transporter type-1 (LAT-1). However more studies and evidence are warranted to investigate the clinical value of BBPA PET imaging in human. This study aim to observe the safety of BBPA, and investigate the diagnostic value of BBPA in the patient with suspected malignant tumors. Patients who meet the eligibility criteria are included in clinical trials after fully communicating the condition, explaining the benefits and risks of clinical trials, clarifying the patient's willingness to include the clinical trial, and signing informed consent. The cohort number, BBPA administrative dose, imaging protocols are decided based on the investigators' preliminary data. The diagnosis and post- examination treatment are based on the recommended guideline, combined with the subject's own situation for standardized diagnosis and treatment


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date September 1, 2024
Est. primary completion date June 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Have suspected diagnosis of brain tumors, based on clinical performance and imaging results. - Meet the indications for PET examination, show a clear indication and no contraindications; - Have a performance status of score =80 on KPS scale or score 0-1 points on ECOG scale, a relatively good general situation; - Does not appear agonal stage, deep coma, over grade 2 major organ dysfunction (heart, lung, liver, kidney and other major organ include), acute or life-threatening status of infection; - Be = 18 years of age on day of signing informed consent. - Be willing and able to understand the research content and provide written informed consent/assent for the trial. Exclusion Criteria: - Have a history of imaging agent allergies; - Does not meet the PET-CT scan sedation requirements, or there are contraindications for PET-CT examination; - Be pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial; - Unable to adhere strictly to protocol requirements.

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
BBPA PET examination
A single dose of 0.10 mCi/kg BBPA will be intravenously injected and PET examination will carry out 30 minutes later.

Locations

Country Name City State
China Wenbin Ma Beijing Beijing

Sponsors (3)

Lead Sponsor Collaborator
Peking Union Medical College Hospital Peking University, Peking University Cancer Hospital & Institute

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary standardized uptake value (SUV) for BBPA SUV reflects the uptake of PET tracers, and quantitative imaging features such as SUVmax, SUVmean, and visually assessed features will be measured in the evaluation of tumors. 1 week
Secondary Adverse events Adverse event within 1 week after BBPA injection will be documented. 1 week
See also
  Status Clinical Trial Phase
Completed NCT02041871 - Interest of PReOPerative Immunonutrition in Liver Surgery for Cancer N/A
Completed NCT03110783 - Bioseal Dural Sealing Study BIOS-14-001 Phase 3
Recruiting NCT05516914 - A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors Phase 1/Phase 2
Completed NCT02534506 - Study of Urelumab in Subjects With Advanced and/or Metastatic Malignant Tumors Phase 1
Recruiting NCT05714748 - Application of mRNA Immunotherapy Technology in Epstein-Barr Virus-related Refractory Malignant Tumors Phase 1
Not yet recruiting NCT01092247 - The Effect of Ketogenic Diet on Malignant Tumors- Recurrence and Progress N/A
Recruiting NCT03160599 - Restricted Calorie Ketogenic Diet as a Treatment in Malignant Tumors N/A
Recruiting NCT04702841 - CAR - γ δ T Cells in the Treatment of Relapsed and Refractory CD7 Positive T Cell-derived Malignant Tumors Early Phase 1
Completed NCT00165100 - Dynamic Area Telethermometry (DAT) as an Imaging Modality in Patients With Cancer N/A
Suspended NCT05615974 - A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors Phase 1/Phase 2
Completed NCT03542773 - Targeted Imaging of Glutamate Carboxypeptidase II With DCFPyL-PET Phase 1
Completed NCT05293990 - Usefulness of Gadovist-enhanced FLAIR Imaging N/A
Completed NCT01509612 - Additive Homeopathy in Cancer Patients Phase 3
Completed NCT01678690 - An Exploratory Study of Gemcitabine Hydrochloride Oral Formulation (D07001-F4) in Subjects With Malignant Tumors Phase 0
Suspended NCT06270394 - FAP PET/CT or PET/MR Production in the Diagnosis, Staging, and Efficacy Assessment of Malignant Tumors Application N/A
Completed NCT00412503 - Temozolomide in Association With Topotecan in Refractory or Relapsed Malignant Tumors in Children and Adolescents Phase 1